Methods and compositions for improving cognitive function

Abstract

This invention relates to treating age-related cognitive impairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam, seletracetam, and brivaracetam, in improving cognitive function in subjects that exhibit age-related cognitive impairment or are at risk thereof, including, without limitation, subjects having or at risk for Mild Cognitive Impairment (MCI), Age-related Cognitive Decline (ARCD) or Age-Associated Memory Impairment (AAMI).

1 - 23 . (canceled) 
     
     
         24 . A pharmaceutical composition comprising 125 mg-250 mg levetiracetam, or a pharmaceutically acceptable salt thereof, wherein the levetiracetam, or the pharmaceutically acceptable salt thereof, in the pharmaceutical composition is formulated in unit dosage form for extended release and oral, once-a-day administration. 
     
     
         25 - 46 . (canceled)